Directions to Ambit Biosciences Corporate Headquarters

Ambit Biosciences is a biotechnology company engaged in discovering, developing and commercializing targeted small molecule therapeutics for the treatment of cancer. Our drug candidates are directed against an important family of enzymes called kinases, known to be involved in a range of human diseases. We are developing our lead drug candidate, quizartinib (formerly AC220), for the treatment of acute myeloid leukemia (AML) under our global collaboration with Astellas Pharma Inc. Quizartinib is a once-daily, orally-administered, potent and selective kinase inhibitor currently in a Phase 2 clinical study in the relapsed/refractory AML patient population. According to the American Cancer Society, approximately 13,000 adults in the US were newly diagnosed with AML in 2009, with approximately 9,000 expected to die of the disease in that year. Quizartinib is being developed as a treatment for the approximately one-third of AML patients with activating mutations in the FLT3 gene that drive a particularly aggressive and deadly form of this disease. We believe a targeted and personalized medicine approach to the treatment of AML has significant potential to improve patient outcomes. In addition to quizartinib, we have a pipeline of kinase inhibitors with potential advantages over existing therapeutics that are aimed at improving patient outcomes in conditions with significant unmet medical need.